Why CRISPR Therapeutics Stock Sank Today

George Budwell, The Motley Fool
·2 min read
Why CRISPR Therapeutics Stock Sank Today
Why CRISPR Therapeutics Stock Sank Today

Shares of clinical-stage biotech CRISPR Therapeutics (NASDAQ: CRSP) are down an eye-popping 12% as of 12:05 p.m. EDT Wednesday. The biotech's shares sank in response to a patient death in an early stage study assessing the company's off-the-shelf T-cell therapy, CTX110, in patients with CD19+ B-cell malignancies (blood cancers). The patient in question was the only one to receive the highest dosage of the experimental cell therapy in the study.